ATTENTION TO CONGENITAL HEART DISEASES IN INFANTS

.
.
ATTENTION TO CONGENITAL HEART DISEASES IN INFANTS

Congenital heart diseases are cited as the most common cause of congenital anomalies seen in newborns, while many parents may experience anxiety about their baby’s heart health. Many congenital heart diseases can be diagnosed early with the fetal echocardiography method, which allows you to examine the baby’s heart while he is still in the womb. In order to prevent the detected heart disease at birth, parents can be directed to the appropriate centers to plan an early and correct intervention. At the Sabanci University, the Turkish lecturer Professor Dr. gave us information about heart problems in infants.

Congenital heart disease (CHD) is a structural disease that occurs early in pregnancy in Turkey and is found in the baby’s heart. While these diseases exist from the moment the baby is born, some of them are mild and only followed up, and some of them are more severe and require treatment. Pay attention to the first two months of pregnancy! The development of the hearts of babies in the womb is observed on the 3rd-8th day of pregnancy. it takes place in the period between. Developmental defects that may occur during this period can lead to congenital heart disease in infants. However, with regard to such conditions as rhythm disturbances, it should be noted that pregnancy is the 2nd. and 3. findings may develop during the trimester periods.

.
PAY ATTENTION TO RISK-INCREASING FACTORS

Some problems and diseases that occur in expectant mothers can cause an anomaly in the heart of their baby. The factors that increase the risk of cardiac anomalies are as follows: – the infant of the mother can cause developmental disorders in which some agents (teratogens) to drugs or infections, exposure to certain drugs and the use of substances, – the mother’s excessive alcohol consumption, – the mother of rubella in the first trimester of pregnancy, have had sitomegalo virus infection, and high-dose ionizing radiation exposure of the mother in the presence of diabetes mellitus (diabetes in the early stages of congenital heart disease in situations where the audit is not performed per cent risk of 0.6-0.8 percent rises to 4-6 percent. This risk ratio is 14 percent for babies of mothers with phenylketonuria disease) – Connective tissue diseases in the mother, -The presence of a family history of congenital heart disease, especially in the mother. Fetal echo can detect abnormalities in the heart of a baby in the womb These abnormalities that can develop in the heart of a baby in the womb can be detected by fetal echocardiography, also called “Fetal echo” for short, which is an ultrasound method. In this method, information about the structural condition and functions of the heart can be obtained through ultrasonic sound waves.

.
CONGENITAL HEART DISEASES ARE AMONG THE MOST COMMON ANOMALIES

Congenital heart diseases are diseases that occur in the process of the baby’s development in the womb. Fetal echocardiography can be used to obtain the findings of some conditions in which the heart is affected secondary to non-cardiac factors such as congenital heart diseases, various rhythm disorders, anemia. While the monitoring rates of CHD, which is one of the most common anomalies present at birth, are in the between of 1-2 percent, the incidence of these diseases in the womb may rise to higher levels. It is a safe method for mother and baby 18-22 weeks of pregnancy is the most suitable time interval for fetal eco application. Fetal echocardiography is performed by imaging the baby’s heart through appropriate probes from the mother’s abdominal surface. There is no harm from this procedure, which is a reliable method for the mother and fetus. In the case of connective tissue diseases and rhythm disturbances, this process is called the 2nd stage of pregnancy. and 3. it is also important to do it during the trimester periods. Fetal echocardiography should be applied to high-risk groups in order to detect congenital heart diseases, it should be applied to high-risk groups. Those with a family history positive for high-risk groups, with some diseases mothers during pregnancy to teratogens (agents) exposure, intrauterine infections such as rubella, passing to be reported fetal abnormalities, amniotic fluid abnormalities, chromosomal abnormalities, the presence of twin pregnancies, and conjoined twins are monozygotic twins. However, fetal echo can be applied to expectant mothers who are older, as well as mothers whose assay results are abnormal.

.
MAKING A DIAGNOSIS AFFECTS THE COURSE OF THE DISEASE AFTER CHILDBIRTH

CHD is one of the most frequently overlooked anomalies in prenatal ultrasound studies. Prenatal diagnosis of these diseases significantly affects the patient’s course after birth, especially in some congenital heart diseases. In addition to ultrasound scans, which are increasing in frequency in the world, fetal heart evaluation is also increasingly in demand. All expectant mothers should undergo fetal echocardiography Fetal echocardiography is performed primarily for expectant mothers who are in the risk group. However, it has been observed that 90 percent of the anomalies found in routine fetal echocardiography scans have been detected in the babies of expectant mothers who do not carry any risk. In other words, the fact that the mother has no risk does not mean that her baby will not have CHD. For this reason, it is important that all expectant mothers undergo fetal echocardiography screening. Many heart diseases are treatable The treatment of many heart diseases is possible today. Treatment options vary depending on the type of anomaly, gestational age, major accompanying anomalies, and ethical status. In cases where congenital heart diseases are detected with fetal echo, an assessment is made according to the state of the pathology. In such cases, where it is necessary to monitor the mother and baby, the parents are referred to the appropriate centers for the necessary intervention in childbirth. Thus, the baby is provided with the planning of an early and correct intervention. 24 In infants with severe heart disease during fetal echocardiography scans. in the period up to a week, families are informed about the option of terminating the pregnancy. Also, when there is a rhythm disturbance in the fetus, the baby’s rhythm is helped by medications prescribed to the mother.

.
.
.
.

Follow me
President of Organ Transplant Center at MedicalPark Hospital Antalya

Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.

Physician's Resume:

Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.

Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.

In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.

Awards:

Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.

Certificates:

Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .

Professional Members:

American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.

Disclaimer:

Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Medically Reviewed by Professor Doctor Alper Demirbaş
Follow me